Karuna Therapeutics, Inc.

Karuna Therapeutics, Inc. (KRTX) priced its initial public offering on Jun 28, 2019 at $16.00 per share, raising $89.2M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $361.2M. Goldman Sachs was lead-left underwriter, joined by Citigroup, Wells Fargo and Wedbush. Goodwin Procter advised the company and Cooley advised the underwriters.

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for neuropsychiatric conditions. Its lead candidate, KarXT, combines xanomeline with trospium to stimulate muscarinic receptors in the central nervous system and is in a Phase 2 trial for acute psychosis in schizophrenia.

Status

IPO

Ticker

KRTX

Exchange

Nasdaq Global Market

Priced

Jun 28, 2019

IPO price

$16.00

Raised

$89.2M

Market cap at IPO price

$361.2M

First filed

May 31, 2019

Underwriters

Goldman Sachs, Citigroup, Wells Fargo and Wedbush

Company counsel

Goodwin Procter

Underwriters' counsel

Cooley

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.